IOP
Beijing, China
IOP
Beijing, China

Time filter

Source Type

News Article | February 28, 2017
Site: www.businesswire.com

LAS VEGAS--(BUSINESS WIRE)--Atlantic Pacific Processing Systems (APPS), a leading U.S. payment solutions provider, today announced it has entered into a strategic partnership with leading Canadian payment processor and merchant services provider CT-Payment. Under the agreement, APPS will be able to offer its U.S. merchant customers payment processing products and services for their Canadian operations from CT-Payment. Likewise, CT-Payment will be able to offer payment processing products and services to its Canadian merchant customers who have U.S. operations through APPS. “Our focus on marquee merchants, the government and municipality vertical market and financial institution partners has enabled us to grow organically into one of the most reliable and successful processors in the business today,” said Abe Maghaguian, chief executive officer for APPS. “We have found a valuable strategic partner in CT-Payment,” added Maghaguian. “We share the same important business values and internal processes, plus offer superior tools and customized payment solutions, which will enable mutual expansion in both the United States and Canada alike.” Through the partnership, merchants, value-added resellers (VARs) and financial institution partners in the United States and Canada gain access to a full suite of payment processing services, competitive pricing structures and dedicated sales support teams. The partnership enhances both companies’ offerings and positions in the high-growth areas of integrated payments, e-commerce and global payment services. APPS provides end-to-end merchant credit card and automated clearing house (ACH) payment solutions and services throughout the United States. The company delivers competitive and scalable customized, cost-effective and efficient transaction processing solutions with superior customer service to save merchants time and money. APPS specializes in multiple vertical markets and works with both value-added resellers (VARs) and financial institution partners. The company is headquartered in Las Vegas, Nevada with operations in Fountain Valley, California. For more information, please visit approcessing.com or email info@approcessing.com. CT-Payment is a leading, independent payment processor. EMV certified and PCI DSS Level 1 compliant, CT-Payment leverages its robust payment network infrastructure and global connectivity to deliver innovative multichannel payment services and solutions to acquirers and the independent sales organizations/member service providers (ISO/MSPs) representing them, independent software vendors (ISVs), payment gateways, merchants and government organizations. CT-Payment’s success is based on being a single-source provider that develops, integrates and deploys a wide range of stand-alone, semi-integrated and integrated point-of-sale (POS), e-commerce and mobile payment solutions. The company also develops proprietary terminals applications and licenses its technology to banks and merchant service providers. CT-Payment is also a direct connector member of Interac, a certified Interac service provider for Interac direct debit and a certified Interac online payments (IOP) acquirer. For more information, please visit ct-payment.com or email marketing@ctpayment.com.


Novel nanoscale transfer printing technique for precise positioning of nanowire lasers Semiconductor nanowires, with lasing emission at room temperature, can be transferred in a controlled way to specific locations on diverse substrates and organized into bespoke spatial patterns. Semiconductor nanowire (NW) lasers provide coherent light sources with highly localized emission and extremely small footprints. Such lasers may thus have the potential to revolutionize the field of photonics.1–3 Indeed, NW lasers are expected to play a key role in future optoelectronic systems, i.e., with applications in nanophotonic integrated circuits for on-chip communications and computing, in ultrasmall laser sensors for healthcare, and in light-cell interfaces for biological sciences.1–3 The extremely small dimensions of NW lasers, however, mean that it is technologically challenging to accurately manipulate and integrate them into functional systems. Their transition from laboratory environments to real-life, industrially relevant products is thus limited. In the past, several approaches have been proposed for the manipulation of NWs. These include optical tweezers,4 Langmuir-Blodgett assembly processes,5 the use of microscope probes,6 or contact printing techniques.7 All these techniques, however, have associated problems. For example, the NWs must be in solution, complex equipment is required, they provide reduced positioning accuracy, they do not allow individual NWs to be manipulated, or heterogeneous NWs cannot be integrated within the same system. The precise, simple, and efficient manipulation of single-NW lasers is thus still to be realized. At the Institute of Photonics (IOP) of the University of Strathclyde, UK, we have thus developed a new technique—known as nanoscale transfer printing (nano-TP)—to tackle the challenge of single-NW laser manipulation.8, 9 Transfer printing technology (originally introduced by John Rogers at the University of Illinois10) involves the use of polymer stamps to capture semiconductor structures in a controlled manner and to subsequently release them onto diverse substrates. This approach provided a revolutionary platform for hybrid fabrication of a wide range of novel optoelectronic systems (e.g., semiconductor lasers printed on silicon substrates11 and LEDs printed on flexible and diamond substrates12). In turn, these systems had a large impact in many different technologies, such as visible light communications, flexible optoelectronics, and photonic integrated circuits. In our nano-TP technique we use bespoke polymer microstamps (μ-stamps), which have reduced dimensions and controlled shapes, to capture/release indium phosphide (InP) NW lasers.13 To fabricate (at the Australian National University) the NW lasers we used in our work, we grew vertically aligned InP NWs on an InP substrate, as shown in Figure 1(a). Before performing our nano-TP study, we removed the NWs from the growth substrate and used mechanical means to randomly scatter them onto a silicon (Si) substrate: see Figure 1(b). The final lasers have a lasing emission—see Figure 1(c)—at room temperature in the ∼840–890nm wavelength range.13 Figure 1. Scanning electron images of indium phosphide (InP) nanowire (NW) lasers that are (a) vertically aligned (as-grown) on an InP substrate and (b) randomly scattered on a silicon (Si) surface. (c) Image of lasing emission (in the 840–890nm range) from the NW lasers. Scanning electron images of indium phosphide (InP) nanowire (NW) lasers that are (a) vertically aligned (as-grown) on an InP substrate and (b) randomly scattered on a silicon (Si) surface. (c) Image of lasing emission (in the 840–890nm range) from the NW lasers. 8 To fabricate our μ-stamps, we used polydimethylsiloxane (PDMS), i.e., an elastomeric and adhesive polymer that conforms to the shape of the NW when pressed against it. The NW therefore adheres to the μ-stamp and enables its capture. After lifting off the NW in our approach, we align the μ-stamp (with the NW attached) at a targeted location on a secondary substrate (where the NW is then released). The different mechanisms and stages of our nano-TP process are illustrated in Figure 2.8 Figure 2. (a) Schematic diagrams illustrating the six stages of the nanoscale transfer printing (nano-TP) technique, i.e., showing (1) alignment of the NW and microstamp (μ-stamp), (2) surface (growth substrate) contact, (3) NW lift-off, (4) alignment of the μ-stamp with the receiving substrate, (5) surface (receiving substrate) contact, and (6) NW release. (b) Sequence of microscope images illustrating the transfer of an InP NW laser (5μm in length, 660nm in diameter) from a Si substrate (left) to a silica surface (right), through pressing with a v-shaped μ-stamp. (a) Schematic diagrams illustrating the six stages of the nanoscale transfer printing (nano-TP) technique, i.e., showing (1) alignment of the NW and microstamp (μ-stamp), (2) surface (growth substrate) contact, (3) NW lift-off, (4) alignment of the μ-stamp with the receiving substrate, (5) surface (receiving substrate) contact, and (6) NW release. (b) Sequence of microscope images illustrating the transfer of an InP NW laser (5μm in length, 660nm in diameter) from a Si substrate (left) to a silica surface (right), through pressing with a v-shaped μ-stamp. 8 We have also used our nano-TP approach to demonstrate the precise transfer of InP NWs that have different dimensions (i.e., diameters of 435, 660, and 920nm) from a primary Si substrate to targeted locations on heterogeneous surfaces (e.g., PDMS, silica, or gold).8 We find that the NWs retain their lasing emission characteristics after the nano-TP process is completed. Furthermore, our technique permits the formation of micrometric spatial patterns from NW lasers on diverse substrates. For example, we show bright and dark micrographs of an ‘IOP’ pattern in Figure 3. We fabricated this pattern—in which all elements (i.e., NWs) kept their lasing emission—with the use of 435nm-diameter InP NWs.8 Figure 3. (a) Bright and (b) dark micrographs of an ‘IOP’ pattern formed from InP NWs on polydimethylsiloxane, through the use of nano-TP. Scale bar marks 20μm. (a) Bright and (b) dark micrographs of an ‘IOP’ pattern formed from InP NWs on polydimethylsiloxane, through the use of nano-TP. Scale bar marks 20μm. 8 In summary, we have developed a novel transfer printing technique—known as nano-TP—that enables precise positioning of NW lasers onto heterogeneous substrates. We can also use our approach to organize the NW lasers into bespoke micrometric patterns. Notably, the NWs retain their lasing emission even after the TP protocols have been completed. Our enabling technology thus opens up potential new routes for accurate integration of NW lasers onto functional nanophotonic systems. Our future plans involve the use of nano-TP to incorporate NW lasers into waveguiding technological platforms, and to thus develop reduced footprint nanophotonic integrated circuits for applications in information and communication technologies (e.g., integrated nanoscale light sources in on-chip communications/computing systems) and healthcare (e.g., nanolaser integrated sensing modules). Financial support for this work was provided by the University of Strathclyde (through the Strathclyde's Chancellor Fellowship Program), the Australian Research Council, and the UK's Engineering and Physical Sciences Research Council (grant EP/I029141/1). We thank the Australian National Fabrication Facility, ACT Node, for access to the growth facilities used in this work. University of Strathclyde Antonio Hurtado has more than 10 years of research experience in photonics in the UK, US, and Spain. He was awarded two prestigious Marie Curie Fellowships by the European Commission and a Strathclyde Chancellor's Fellowship, after which he was appointed as lecturer in the University of Strathclyde's Institute of Photonics. 4. P. J. Pauzauskie, A. Radenovic, E. Trepagnier, H. Shroff, P. Yang, J. Liphardt, Optical trapping and integration of semiconductor nanowire assemblies in water, Nat. Mater. 5, p. 97-101, 2006. 5. S. Jin, D. Whang, M. C. McAlpine, R. S. Friedman, Y. Wu, C. M. Lieber, Scalable interconnection and integration of nanowire devices without registration, Nano Lett. 4, p. 915-919, 2004. 6. H. Xu, A. Hurtado, J. B. Wright, C. Li, S. Liu, J. J. Figiel, T.-S. Luk, et al., Polarization control in GaN nanowire lasers, Opt. Express 22, p. 19198-19203, 2014. 7. Z. Fan, J. C. Ho, Z. A. Jacobson, R. Yerushalmi, R. L. Alley, H. Razavi, A. Javey, Wafer-scale assembly of highly ordered semiconductor nanowire arrays by contact printing, Nano Lett. 8, p. 20-25, 2008. 8. B. Guilhabert, A. Hurtado, D. Jevtics, Q. Gao, H. H. Tan, C. Jagadish, M. D. Dawson, Transfer printing of semiconductor nanowires with lasing emission for controllable nanophotonic device fabrication, ACS Nano 10, p. 3951-3958, 2016. 9. A. Hurtado, B. J. E. Guilhabert, M. J. Strain, N. Laurand, C. Jagadish, M. D. Dawson, Nanoscale transfer printing for heterogeneous device integration. Presented at SPIE Photonics West 2017. 10. M. A. Meitl, Z.-T. Zhu, V. Kumar, K. J. Lee, X. Feng, Y. Y. Huang, I. Adesida, R. G. Nuzzo, J. A. Rogers, Transfer printing by kinetic control of adhesion to an elastomeric stamp, Nat. Mater. 5, p. 33-38, 2006. 11. X. Sheng, C. Robert, S. Wang, G. Pakeltis, B. Corbett, J. A. Rogers, Transfer printing of fully formed thin-film microscale GaAs lasers on silicon with a thermally conductive interface material, Laser Photon. Rev. 9, p. L17-L22, 2015. 12. A. J. Trindade, B. Guilhabert, E. Y. Xie, R. Ferreira, J. J. D. McKendry, D. Zhu, N. Laurand, et al., Heterogeneous integration of gallium nitride light-emitting diodes on diamond and silica by transfer printing, Opt. Express 23, p. 9329-9338, 2015. 13. Q. Gao, D. Saxena, F. Wang, L. Fu, S. Mokkapati, Y. Guo, L. Li, et al., Selective-area epitaxy of pure wurtzite InP nanowires: high quantum efficiency and room-temperature lasing, Nano Lett. 14, p. 5206-5211, 2014.


BAUSCH + LOMB AND NICOX RESUBMIT US NEW DRUG APPLICATION FOR NOVEL GLAUCOMA CANDIDATE LATANOPROSTENE BUNOD LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE - FEBRUARY 27, 2017 - Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma (OAG) or ocular hypertension (OHT). The data submitted in the NDA support latanoprostene bunod as the first nitric-oxide donating prostaglandin F2alpha analog for ophthalmic use. Latanoprostene bunod was licensed by Nicox to Bausch + Lomb. About Latanoprostene Bunod             Latanoprostene bunod ophthalmic solution, 0.024% is an IOP-lowering single-agent eye drop dosed once daily for patients with OAG or OHT. In the eye, latanoprostene bunod is metabolized to two moieties. The first, latanoprost acid, is an F2alpha prostaglandin analog, while the second, butanediol mononitrate, releases nitric oxide, which activates the soluble guanylate cyclase-guanosine-3',5'-monophosphate signaling pathway. Latanoprostene bunod is believed to lower IOP by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. About Glaucoma             Glaucoma is a group of eye diseases which can lead to the loss of peripheral vision and eventually total blindness. Glaucoma is frequently linked to abnormally high pressure in the eye (intraocular pressure, IOP), due to blockage or malfunction of the eye's drainage system. Abnormally high IOP does not cause any symptoms itself, however it can lead to optic nerve damage and vision loss over time if left untreated. Drug therapy is used to reduce IOP and therefore prevent further vision loss, typically through either reducing aqueous humor production or by increasing the drainage of intraocular fluid by relaxing certain muscles in the eye. Several large trials have demonstrated that reducing IOP can prevent the progression of glaucoma in both early and late stages of the disease. A significant proportion of patients with elevated IOP require more than one medication to maintain their IOP within target levels, highlighting the need for more effective treatments. About Valeant             Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com. About Bausch + Lomb             Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries. About Nicox   Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health.   By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma.  Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com . Forward-looking Statements This press release contains forward-looking statements.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements.  These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.


News Article | February 21, 2017
Site: globenewswire.com

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017   Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy. NCX 667, synthesized by Nicox, is the lead compound of a new class of next-generation stand-alone NO-donors, which are designed to optimize NO dosing and enable intraocular pressure (IOP) lowering in patients with open angle glaucoma (OAG) or ocular hypertension.  The AOPT 2017 abstract by Impagnatiello et al1 presented preclinical results obtained with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma following single and repeated treatment schedules. NCX 667 appeared to lower IOP by 20% or more regardless of the specific model and animal species used. Furthermore, repeated acute dosing of NCX 667 elicits sustained IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.   Data from a variety of experimental animal models coupled with recent clinical studies strongly support an important role of NO in lowering IOP by enhancing aqueous humor drainage via the conventional outflow route. Open angle glaucoma is a common ocular disorder affecting about 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide.2   Developed by Nicox, NCX 667 already demonstrated promising preclinical results in two preclinical models of ocular hypertension and glaucoma. In both models, NCX 667 appeared well-tolerated and effective in reducing intra-ocular pressure (IOP). These results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', as representing the newest and most innovative research being conducted. Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health.   By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma.  Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com. March 6-8  Cowen and Company 37th Annual Health Care Conference  Boston, US March 21-22  Oppenheimer 27th Annual Healthcare Conference  New York, US  April 4-5  Needham's 16th Annual Healthcare Conference New York, US May 30   Gilbert Dupont 15th Annual Helthcare Conference  Paris, France  June 19-22  2017 BIO International Convention  San Diego, US The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.


News Article | February 15, 2017
Site: www.businesswire.com

PALO ALTO, Calif.--(BUSINESS WIRE)--Thanks to the outstanding philanthropic leadership of an anonymous Palo Alto resident, CHC is moving forward with plans to launch Palo Alto’s first Intensive Outpatient Program (IOP) this spring, filling a critical gap in teen mental health services. The IOP, located on CHC’s campus, will address the needs of teens between the ages of 14-18 with significant anxiety, depression, and/or suicidal thoughts. “We are in the perfect place to do this, we have the qualified staff to do it, and now, thanks to a generous lead donor, we can move forward right away, knowing that it will be accessible and affordable to all teens, regardless of financial capacity,” said CHC’s Executive Director, Dr. Rosalie Whitlock. After a recent qualitative study revealed a significant need for a Palo Alto-based intensive after school therapy program for teens, CHC was driven to add an IOP to its robust web of support for at-risk teens. It is a natural extension of CHC’s comprehensive continuum of care and overall commitment to helping local youth realize their promise and potential. “It was time to listen to our community by creating a local resource that can meet the mental health needs of our struggling teens,” said Dr. Ramsey Khasho, Director of The Center at CHC. CHC’s skilled adolescent psychiatrists and expert teen therapists will allow for seamless transitions between the IOP and less intensive outpatient therapy services. “CHC is a natural home for an IOP because we have appropriate space, knowledge and skill sets along with the passion and heart for the community and our teens,” said Dr. Lynette Hsu, Head of Adolescent Mental Health Services at CHC. CHC’s twelve-week IOP will be able to accommodate up to eight teens at a time and will be offered on a rolling basis, four days/week during after-school hours, enabling teens to maintain their daily school routines. The IOP’s therapeutic multimodal approach includes evidence-based interventions including Dialectical Behavior Therapy (DBT)—considered the IOP gold standard for psychological treatment of mental health disorders—and Cognitive Behavior Therapy (CBT), as well as best practices in mindfulness. Seasoned, licensed clinicians trained through the Linehan Institute (founded by Marsha Linehan, Ph.D., the developer of DBT therapies), will provide individual, group, and family therapy; psychiatry with medication management; an academic skills component; mindfulness training (physical, art, nutrition); and parent and multi-family skill groups. Those who will benefit most from CHC’s IOP include teens with moderate to severe symptoms of anxiety or depression; self-harm behaviors (i.e. cutting); suicidal thoughts with or without plans; significant decrease in functioning at school and at home (i.e. sharp decline in grades, missing school); and those for whom weekly outpatient therapy is not effective for symptom reduction and improved functioning. The program covers the often overlooked but essential middle ground between weekly outpatient therapy and hospitalization, and provides transition support between the two. The program also provides a critical step-down service for teens discharged and returning from psychiatric inpatient stays. Because teen anxiety and depression symptoms are not clear-cut and many parents may not know what level of help their teen needs, CHC is also expanding its free 30-minute expert consultation service. “We want to offer clarity and comfort during what can be a scary and confusing time for parents,” said Dr. Khasho. Parents are encouraged to call, even if they aren’t certain whether their teen is exhibiting typical adolescent behavior or warning signs of something more serious. Connecting those in need with those who can help is the cornerstone of CHC’s Teen Mental Health Initiative (TMHI) of which the IOP will be an integral part. TMHI also aims to remove stigma, raise awareness and reduce teen suicide through accessible, affordable and compassionate teen therapy; community education; and community engagement. “Teen mental health is not an issue that can be tackled by CHC alone,” said Dr. Whitlock. “In order to make a lasting impact, we need to educate ourselves and each other, leverage strengths and partnerships, and involve all stakeholders—from teens and teachers to parents and government officials.” On this front, CHC has incorporated 12 new teen-focused classes into its free community education program (link); launched a Teen Mental Health Committee, made up of local teens who want to use their voices to reduce stigma and advocate change; partnered with Stanford to develop a Teen Mental Health Leadership Collaborative of local leaders of various stakeholder groups to leverage the community’s collective strengths and make advancements in the Bay Area teen mental health system of care; and hosts regular gatherings with local school counselors and wellness coordinators to understand and address unmet mental health needs at the school and district level. A complex problem deserves a comprehensive solution, and a changing landscape requires a nimble strategy. “We are not interested in a band-aid fix,” said Dr. Khasho. “We won’t rest until we see meaningful and lasting results.” In addition to CHC’s award-winning education and mental healthcare services, CHC has long been a community resource. On March 16th, CHC will host its annual community breakfast featuring guest speakers Nancy Lublin, Founder and CEO of the acclaimed Crisis Text Line, the 24-hour crisis intervention service delivered via text; Jayne Apple, WNBA Star and founder of Bring Change 2 Mind, a non-profit working to end the stigma and discrimination surrounding mental illness; James B. Everitt, EdD, Director, Office of Mission Initiatives & Institutional Planning for Sacred Heart Schools, which oversees the School’s health and wellness efforts; and Ramsey Khasho, PsyD, CHC Director of The Center & Director of Clinical Services, Sand Hill School. Over the next year CHC will continue to bring the community together through education, expert panels, breakfast meetings and other events to highlight the various needs of teens. Ongoing developments and details about the CHC Teen Mental Health Initiative and the new IOP may be found at www.chconline.org. To schedule a free 30 minute consultation or an appointment for services call 650.688.3625 or email help@chconline.org. CHC is a nonprofit agency that has been serving children, youth, teens and young adults in San Mateo and Santa Clara Counties as well as the greater San Francisco Bay Area for nearly 65 years. The CHC Teen Mental Health Initiative expands affordable teen therapy, mental health education, and community leadership and engagement directly, and through community collaborations, to help reduce teen anxiety and depression, and prevent teen suicide. The goal of the agency is to remove barriers to learning regardless of language, location, learning style or ability to pay. The agency specializes in Anxiety & Depression, ADHD, Learning Differences, and Autism with The Center, two schools, Community Clinic and Community Education. www.chconline.org


News Article | February 28, 2017
Site: www.realwire.com

Forum’s work helps operators plot path to densification for today’s 4G and future 5G networks Mobile World Congress, Barcelona, Spain – 28th February 2017 – SCF has today published a series of practical working guides to make densification using small cells a commercial reality, both for today’s 4G and for future 5G networks. These latest outputs go further than ever before in articulating the work the Forum is undertaking to increase the success of current small cell technologies, while applying knowledge gained to ensure that networks of the future are practical and profitable for all parties concerned. The full documentation is available from http://scf.io While 5G standards are still being defined, it is clear that network densification is fundamental to meeting the cardinal requirements of high capacity, low latency and 100% coverage. These new outputs outline SCF’s activities in addressing technical, practical and commercial barriers to densification which include: “The mobile industry is in agreement that network densification is fundamental to adding capacity to today’s 4G networks, as well as building out the foundations for 5G,” said David Orloff, Chair of Small Cell Forum. “However, this can’t happen without the physical deployment of more network assets, the technologies to manage them and the testing to make them interoperable. These guides provide an informed perspective on the real-world experience of deploying 4G that will ensure 5G hits the ground running.” As well as identifying and expanding upon the key role densification will play in driving future networks, these publications detail what it takes for operators and the enterprise to commercially deploy a Hyperdense network today; including comprehensive explanations of regulatory, logistical and operational considerations. The Release highlights the success of SCF’s crucial ecosystem building activities thus far, including clarifying pre-deployment requirements for – and the value proposition of – small cells. The Forum has taken the lead in defining standards, deployment and operation, lobbying regulators and policy makers to cut red tape, driving consensus where fragmentation is stalling process, educating the market and conducting IOP testing to ensure interoperability. “Small Cell Forum embodies joined-up thinking that ensures small cell technology is not just performant, but practical and profitable too,” said Sue Monahan, CEO Small Cell Forum. “The Forum has a cross-functional approach, allowing our activities’ to span operations, business principles, market concerns, technology (particularly concerning applicability to 5G) and interoperability. We are constantly at work to make sure the best possible solutions are being deployed. Whether it is our activities in devising scalable, repeatable deployment processes to lower cost and lead time or building these practical and commercial learnings into future technologies such as 5G.” About SCF Small Cell Forum works to drive the wide-scale adoption of small cells and accelerate the delivery of integrated HetNets. Our work program is organized around two main streams – Deploying Hyperdense HetNets and Enabling Digitized Enterprise. These tie together all the Forum’s projects across the HetNet and create a powerful framework for the transition to 5G. We are a carrier-led organization. This means our operator members establish requirements that drive the activities and outputs of our technical groups. Today our members are driving solutions that include small cell/Wi-Fi integration, SON evolution, virtualization of the small cell layer, driving mass adoption via multi-operator neutral host, ensuring a common approach to service APIs to drive commercialization and the integration of small cells into 5G standards evolution.


News Article | February 21, 2017
Site: globenewswire.com

February 21, 2017    Sophia Antipolis, France   Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy. NCX 667, synthesized by Nicox, is the lead compound of a new class of next-generation stand-alone NO-donors, which are designed to optimize NO dosing and enable intraocular pressure (IOP) lowering in patients with open angle glaucoma (OAG) or ocular hypertension.   The AOPT 2017 abstract by Impagnatiello et al1 presented preclinical results obtained with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma following single and repeated treatment schedules. NCX 667 appeared to lower IOP by 20% or more regardless of the specific model and animal species used. Furthermore, repeated acute dosing of NCX 667 elicits sustained IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.   Data from a variety of experimental animal models coupled with recent clinical studies strongly support an important role of NO in lowering IOP by enhancing aqueous humor drainage via the conventional outflow route.   Open angle glaucoma is a common ocular disorder affecting about 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide.2   About NCX 667   Developed by Nicox, NCX 667 already demonstrated promising preclinical results in two preclinical models of ocular hypertension and glaucoma. In both models, NCX 667 appeared well-tolerated and effective in reducing intra-ocular pressure (IOP). These results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', as representing the newest and most innovative research being conducted.     Notes: NCX 667, a lead nitric oxide (NO)-donating compound for a new class of ocular hypotensive agents   F. Impagnatiello1, E. Bastia1, N. Almirante1, C. Toris2, C. Lanzi3, E. Ongini1, E. Masini3, M.V.W Bergamini4   1Nicox Research Institute, Milan, Italy; 2Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, USA; 3Department of NEUROFARBA, University of Florence, Florence, Italy; 4Nicox Ophthalmics, Inc., Fort Worth, TX, USA Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


News Article | March 2, 2017
Site: www.businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in March. The presentations and fireside discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days. Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was resubmitted in February 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place in late 2017 or early 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.


News Article | February 15, 2017
Site: www.businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer, will present in a fireside chat discussion at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22, 2017 at 8:30 a.m. Eastern Time in New York, NY. Dr. Kopczynski will provide his perspective on Aerie’s lead product candidates, as well as ongoing pre-clinical activities. The fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days. Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted near the end of the first quarter of 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.


IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the “Company”), announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on Tuesday, March 7, 2017. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company's website at http://investors.aeriepharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 61259874. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 61259874. The telephone replay will be available until March 14, 2017. Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted near the end of the first quarter of 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

Loading IOP collaborators
Loading IOP collaborators